Colgate-PalmoliveKimberly-Clark

Colgate-Palmolive vs Kimberly-Clark

Global oral care and household products leader vs Global maker of tissue and personal care products. Which is the better buy for your portfolio in July 2026? Plain-English answer below.

Colgate-Palmolive defends global oral care and personal hygiene franchises with pricing power that's proven resilient through multiple inflationary cycles while Kimberly-Clark sells diapers, tissues, ...

Why It’s Moving

Colgate-Palmolive

Colgate-Palmolive is under pressure as valuation worries outweigh its steady growth story.

  • Analysts are flagging Colgate-Palmolive as expensive after a long rally, arguing the stock’s valuation now leaves less room for upside and more room for disappointment.
  • The bearish case centers on growth that has been driven more by price increases than by higher product volume, which raises questions about how durable the company’s momentum really is.
  • Margin gains may be nearing a peak, and in a higher-rate market, the stock’s low dividend yield looks less compelling versus its valuation, adding to downside risk concerns.
Sentiment:
🐻Bearish
Kimberly-Clark

Kimberly-Clark moves on mixed analyst views as investors weigh defensive stability against limited growth

  • Analyst sentiment remains mixed, with several firms still rating Kimberly-Clark around Hold, which suggests investors are focused on steady cash generation rather than a sharp rerating.
  • Recent forecast updates show a wide range of price expectations, reflecting disagreement over how much growth is left after the stock’s defensive performance and recent valuation changes.
  • The stock’s move appears tied more to broader consumer-staples positioning than to a fresh catalyst in the past week, with traders weighing defensive demand against slower growth expectations.
Sentiment:
⚖️Neutral

Investment Analysis

Pros

  • Colgate-Palmolive's revenue increased by over 3% in 2024 to $20.1 billion, showing steady top-line growth.
  • The company has a strong dividend yield of approximately 2.7%, providing consistent income to investors.
  • Colgate-Palmolive benefits from a diversified product portfolio spanning oral care, personal care, home care, and pet nutrition.

Considerations

  • The stock trades at a relatively high price-to-earnings ratio around 21.5, which may indicate overvaluation versus peers.
  • Colgate-Palmolive has a higher debt-to-equity ratio that could imply greater financial leverage risks.
  • The company's stock price has shown limited appreciation over the past year, suggesting growth limitations in current market conditions.

Pros

  • Kimberly-Clark is ranked highly on fundamental stock indicators, reflecting strong financial health and operational performance.
  • The company has moderate correlation with Colgate-Palmolive, offering potential portfolio diversification benefits.
  • Kimberly-Clark maintains a solid market capitalization near $44 billion, supporting its stable industry position.

Considerations

  • Kimberly-Clark’s year-to-date and annual stock performance have been lower compared to Colgate-Palmolive, indicating weaker recent momentum.
  • The stock shows moderate beta and volatility, which may lead to higher risk than more defensive consumer staple peers.
  • Limited recent growth catalysts have constrained Kimberly-Clark’s ability to outpace competitors in consumer goods.

Colgate-Palmolive (CL) Next Earnings Date

Colgate-Palmolive (CL) is expected to report next on July 31, 2026, with some sources listing August 7, 2026 as an alternative estimate. The upcoming release should cover Q2 2026 results. The most commonly cited schedule points to a late-July announcement before the market opens.

Kimberly-Clark (KMB) Next Earnings Date

Kimberly-Clark’s next earnings release is typically expected in late July to early August 2026, with current estimates clustering around July 28, 2026 to August 7, 2026. The report will cover Q2 2026 results, based on the company’s quarterly reporting cycle following its Q1 2026 release in late April. If the company has not formally confirmed a date, the most defensible expectation is an announcement in the final week of July or first week of August.

Buy CL or KMB in Nemo

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions

CL
CL$93.60
vs
KMB
KMB$113.83
Buy CL